Drug intelligence / Profile preview

fungal HSF1 inhibitor

Development stage: Preclinical
Lead developer: Sisu Pharma
Modality: Small Molecules

Overview

Sisu Pharma is developing a small-molecule inhibitor targeting the fungal ortholog of Heat Shock Factor 1 (HSF1) for the treatment of fungal infections. HSF1 is a master regulator of the proteotoxic stress response, and in fungi, it is essential for viability and virulence, particularly in adapting to the host environment. By selectively targeting the fungal version of this transcription factor, the drug aims to disrupt the fungal stress response and survival mechanisms without affecting the human HSF1 counterpart. The program is currently in the preclinical stage of development.

Targets

HSF1 (Heat shock factor protein 1)

Beyond the preview

Go deeper on fungal HSF1 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fungal HSF1 inhibitor.

Explore the full profile